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Treatment of intractable seizures other than spasms is difficult and controversial. 
There are few studies on efficacy of adrenocorticotropic hormone (ACTH) in 
treatment of patients with intractable seizure.
Materials & Methods
Twenty-five patients with intractable seizure other than spasm including 14 
boys and 11 girls with median age of 58 months referred to university clinics 
of Pediatric Neurology in Isfahan, Iran, during 2014-2015 were prospectively 
investigated. ACTH was administrated according to our protocol. All cases 
were followed regularly and assessed for response to treatment and probable 
side effects, 3 wk after beginning of ACTH therapy and three months after the 
ACTH therapy. EEG finding were recorded before and three months after the 
end of ACTH therapy. Statistical analysis using Freidman test and Wilcoxon 
signed – rank test were performed in order to compare seizure frequency and 
EEG changes, respectively.
results
Mean A significant reduction (>80%) in seizure frequency in 11 cases (44%) 
and moderate reduction (50%-80%) in 7 (28%) after 3 wk of ACTH therapy. 
Despite initial positive response, recurrence of seizure was observed in 7 out of 
18 cases with favorable initial response within 3 months after ACTH therapy 
cessation. The comparison of EEG finding before and 3 months after ACTH 
therapy using Wilcoxon signed – rank test showed significant differences . 
Conclusion
ACTH therapy may be useful in treatment of children with intractable seizures 
who are resistant to usual antiepileptic drugs. However further studies should 
be performed to determine the long-term efficacy of ACTH in treatment of 
intractable seizure.
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introduction 
Epilepsy and epileptic syndromes are a heterogeneous group of conditions with 
a prevalence of 5.3- 8.8 per 1000 in children below 13 yr of age (1, 2). Overall, 
20%-25% of epileptic patients are resistant to all classical antiepileptic drugs. An 
intractable seizure is defined by therapeutic failure of seizure freedom in response 
to two tolerated and appropriately chosen antiepileptic drugs at reasonable doses. 
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enrolled into this study. 
Inclusion criteria were as follows: Age 1 month-14 
yr; severe intractability; severely abnormal EEG; 
absence of contraindication for ACTH (renal failure, 
hypertension, cardiac failure, serious infection, peptic 
ulcer disease, diabetes mellitus...); and Close follow-up.
Exclusion criteria were severe complication to ACTH: 
hyperglycemia, hypertension, serious infection; loss of 
close follow-up; Infantile spasm; and partial seizures 
with no accompanying generalized seizure.
Seizure frequency was recorded for a period of 2 wk 
by patient’s parents before initiation of treatment with 
ACTH. For all patients, EEG was recorded before 
treatment. 
They received ACTH therapy with synacthen ampule 
1mg/1 ml, according to our protocol consisted the dose 
of 25mcg/kg/day for duration of one week, 12.5 mcg/
kg/day for three days, 12.5 mcg /kg every other day for 
4 d, 12.5 mcg/kg every week for duration of 4 wk and 
6 mcg/kg every week for duration of 4 wk. Standard 
treatment with anticonvulsants continued during period 
of treatment with ACTH for all patients. 
All of the cases were followed regularly in Subspecialty 
Clinic of Pediatric Neurology and evaluated for seizure 
control and probable side effects. Laboratory tests for 
probable side effects including Na, K, BS, BUN, Cr, 
Ca, p, alp, CBC, ESR, CRP was performed 3, 7, 14 d 
after beginning of treatment. 
EEG finding were recorded before, after termination of 
ACTH therapy and three months later. All 25 cases had 
intractable seizure with multiple daily recurrence and 
severely abnormal EEG before ACTH therapy. 
Clinical features of patients including sex, age at 
onset of seizure, developmental status, and etiology 
of epilepsy, MRI findings and prior history of west 
syndrome are shown in Table 1. 
After ACTH, therapy patients were categorized into 
four groups according to their response to treatment. 
Group 1 with excellent response (more than 80% 
reduction in seizure frequency), group 2 with moderate 
response (50%-80% reduction in seizure frequency), 
group 3 with mild response (20%-50% reduction in 
seizure frequency) and group 4 with minimal response 
or no response.
EEG recording was performed in all cases before and 
Frequency of seizures and duration of non-controlled 
epilepsy was considered as criteria for intractable seizure 
(1, 3).
Although corticosteroids and adrenocorticotropic 
hormone (ACTH) as a treatment option are used 
in different epilepsies and epileptic syndromes, the 
efficacy of ACTH and steroids in controlling intractable 
seizure other than spasms has been studied only in 
few studies (4-8). ACTH therapy is also effective for 
epilepsies other than infantile spasm (6, 9-13).
In this article, we report our experience using ACTH in 
the treatment of 25 patients with generalized seizures 
other than spasms who had been refractory to all usual 
AEDs.
Materials & Methods
Twenty-five patients with intractable seizure other than 
spasm including 14 boys and 11 girls with median age 
of 58 months referred to university clinics of pediatric 
neurology in Isfahan, Iran, during 2014-2015 were 
prospectively investigated in this study. 
The protocol of the study was approved by the 
Paediatrics Review Board and the Regional Ethics 
Committee of Isfahan University of Medical Sciences 
(Research Project Number: 394156). Written informed 
consent was obtained from the parents of selected 
patients after describing the goal of and treatments in 
the study. 
Their seizures were refractory to all appropriate 
antiepileptic drugs including valproate, levetiracetam, 
ethosuximide, topiramate, lamotrigine, clonazepam, 
clobazam, nitrazepam, zonisamide, and acetazolamide. 
In six cases, ketogenic diet had been tried with no 
therapeutic effect. These patients had shown no 
effective response to combination therapy of at least 
two of these drugs before ACTH administration. 
In this study design, the arbitrary phrase “multiple daily 
recurrences” was defined as more than ten episodes of 
seizures per week. Severely intractable epilepsy was 
defined as multiple daily recurrences and no response 
to all appropriate anticonvulsants. Severely abnormal 
EEG was defined as EEGs with more than 80% of 
tracing being covered with epileptic discharges.
The patient with multiple daily recurrences and no 
response to all appropriate anticonvulsants were 
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for antiepileptic action of ACTH; however, the 
precise mechanism is not fully understood. ACTH 
acts as a neuropeptide within the brain and it directly 
may have anti-convulsive properties (14). It also 
stimulates the synthesis of two allosteric modulators 
of GABA-A receptors including deoxycorticosterone 
and tetrahydroxy-corticosterone (15). ACTH has 
been demonstrated to down-regulate the expression 
of corticotrophin-releasing hormone (CRH) which 
results in reduction of pro convulsant activity in 
the developing brain (16). In addition, ACTH may 
stimulate glucocorticoid synthesis. Interaction of 
glucocorticoid with central nervous system steroid 
receptors is supposed to influence voltage-dependent 
calcium channels (17). 
Totally, 72% of patients achieved favorable response 
(>50% reduction of seizure frequency) in short-term 
to ACTH therapy. Follow-up of the patients, 3 months 
after stopping ACTH therapy, showed recurrence 
of seizure in 38% of early responders. The excellent 
effectiveness of ACTH in treatment of infantile spasm 
but there are only a few studies on effectiveness of 
ACTH in treatment of patients with intractable seizure 
other than spasm.
Snead et al. described their experience of treatment of 
intractable seizure other than spasms with prednisolone 
or ACTH. In their study, successful cessation of seizure 
was achieved in 74% of patients ACTH therapy and 
in none of the patients treated with prednisolone (5). 
Sinclair used prednisone for treatment of 28 cases 
with intractable epilepsy. During follow-up period 
of 1 to 5 yr, 46% of the patients became seizure free 
and significant decrease in seizure frequency was 
observed in 40% (18). Steroids were administrated on 
the treatment of epilepsy beyond infantile spasm in 32 
children with intractable seizure. In a study, 25% cases 
became seizure free, 11% had a seizure reduction of 
>50% and 11% had a seizure reduction of <50% (7). 
Fifteen children were studied with intractable seizure 
other than spasm. The seizure was controlled in 13 
cases by ACTH therapy but recurrence of seizures was 
observed in 6 of them within 3 months after stopping 
ACTH therapy (6). Successful use of ACTH was 
described in two patients with generalized epilepsy 
who had refractory to multiple AED (13). 
after ACTH therapy. 
Short and long-term effects of ACTH therapy for all 25 
patients were compared using Freidman test. Wilcoxon 
signed–rank test was used for comparison of EEG 
results before and after of ACTH therapy. 
results
Responses to ACTH therapy were evaluated 3 wk 
after initiation and 3 months after cessation of ACTH 
therapy (Table 2). Among 25 patients who had 
intractable seizure with multiple daily recurrences 
before ACTH therapy, 18 cases showed more than 50% 
reduction in seizure frequency 3 wk after initiation 
of ACTH therapy. However, in 7 of 18 cases (38%), 
relapse of seizures was observed within 3 months 
after end of ACTH therapy. Four of eleven cases 
with excellent response (more than 80% reduction 
in seizure frequency) and 3 of 7 cases with moderate 
response (50%-80% reduction in seizure frequency) 
showed relapse of seizures 3 months after cessation of 
treatment. In seven cases (38%), no or little (<20%) 
reduction in seizure frequency was observed 3 months 
after termination of treatment with ACTH. Reduction 
in seizure frequency after ACTH therapy was shown 
in Table 3.
Before treatment, all of the patients had severely 
abnormal EEG with most of tracing being covered by 
epileptic discharges. Repeat EEG 3 months after the end 
of treatment demonstrated more than 50% reduction of 
epileptic discharge in 16 of 25 (64%) cases. 
In this study, there was no relationship between 
response to ACTH and baseline variables including 
age, brain MRI, underlying disease and developmental 
status (P>0.05).
Side effects of ACTH therapy including severe 
irritability, edema and weight gain with frequencies of 
52%, 71%, and 61% were observed respectively (Table 
4). Recurrence of seizure was reported before the next 
dose of ACTH during period of weekly injections in 
three cases with moderate initial response. 
Discussion
ACTH is considered as one of the most effective 
available agents in controlling of intractable seizure 
(5, 7, 14). Various mechanisms have been suggested 
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status etiology epilepsy syndrome Mri results Comments
1 F 7 63 Moderate delay Genetic anomaly Absence- tonic-GTC Normal
2 M 21 78 Severe delay Encephalitis Myoclonic-tonic Diffuse atrophy
3 M 3 22 Severe delay Prematurityhypoxic-ischemic encephalopathy Myoclonic-tonic-GTC
Hypoxic-ischemic chan e
PVL
4 M 6 36 Severe delay Unknown Myoclonic Normal History of West syndrome




6 M 24 57 Severe delay Hypoxic-ischemic en-cephalopathy Myoclonic-tonic Hypoxic-ischemic change
7 M 9 35 Moderate MR Cerebral dysgenesis Myoclonic-GTC Pachygyria History of West syndrome
8 F 11 67 Severe delay Unknown Myoclonic-GTC-tonic Mild atrophy
9 M 8 38 Moderate delay Unknown Myoclonic-atonic Normal History of West syndrome
10 F 7 44 Severe delay Cerebral dysgenesis Atonic-tonic-Myoclonic- Pachygyria
11 F 3 74 Moderate delay Hypoxic-ischemic encephalopathy Myoclonic-GTC
Hypoxic-ischemic change
PVL
12 M 1 28 Severe delay Syndromic anomaly Tonic-GTC-Atonic-myoclonic Normal
13 F 3 39 Moderate delay Unkown Myoclonic-absence-GTC Mild atrophy
14 M 1 48 Severe delay Unknown Myoclonic-tonic-GTC Atrophy
15 F 7 112 Moderate delay Genetic anomaly Myoclonic -absence-partial Normal
16 M 1 32 Severe delay Hypoxic-ischemic encephalopathy Tonic-myoclonic
Hypoxic-ischemic change
PVL
17 M 20 45 Severe delay Cerebral dysgenesisMicrocephaly Myoclonic Polymicrogyria
18 M 8 27 Moderate delay Hypoxic-ischemic encephalopathy Partial-GTC
Mild Hypoxic-ischemic 
change   PVL
19 F 5 94 Moderate delay Unknown Myoclonic-tonic-GTC Mild atrophy
20 F 1 48 Severe delay Cerebral dysgenesis Myoclonic-tonic-absence Cerebral dysgenesis




22 M 8 67 Moderate delay Cerebral dysgenesis Myoclonic-GTC Pachygyria polymicro-gyria
23 F 5 56 Severe delay Genetic anomaly Myoclonic-atonic Normal
24 F 9 123 Severe delay Unknown Myoclonic-atonic Normal
25 F 18 108 Severe delay Genetic anomaly Tonic-Atonic-GTC-absence Normal 
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Percent of reduction of 
seizure frequency(3 w after 
beginning of aCTh)
Percent of reduction 
of seizure frequency (3 months 
after the end of aCTh therapy)
1 Continuous spike and wave discharge >80 >80 
2 Diffuse Poly spike wave >80 >80 
3 Diffuse Poly spike wave >80 
20-50 
4 Diffuse Poly spike wave >80 >80 
5 Diffuse slow spike wave >80 >80 
6 Diffuse slow spike wave >80 
>80 
7 Diffuse Poly spike wave >80 
50-80 
8 Diffuse slow spike wave >80 
20-50 
9 Continuous spike and wave discharge >80 >80 
10 Diffuse Poly spike wave >80 
20-50 
11 Diffuse Poly spike wave >80 >80 
12 Diffuse slow spike wave
50-80 50-80 
13 Diffuse slow spike wave
50-80 
>80 
14 Diffuse slow spike wave
50-80 20-50 
15 Diffuse slow spike wave
50-80 50-80 
16 Diffuse slow spike wave
50-80 <20 
17 Diffuse slow spike wave
50-80 50-80 
18 Continuous partial spike
50-80 
<20 
19 Diffuse slow spike wave
20-50 50-80 





22 Diffuse slow spike wave
<20 <20 
23 Diffuse Poly spike wave <20 <20 
24 Diffuse slow spike wave <20 
<20 
25 Diffuse slow spike wave <20 
<20 
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Table 3. Reduction in seizure frequency after ACTH 
reduction in seizure frequency (%)
3 weeks after





>80 11 (44) 8 (32)
50-80 7 (28) 5 (20)
20-50 3 (12) 4 (16)
<20 4 (16) 8 (32)
Table 4. Side effects of ACTH therapy










Recurrence of seizures before next dose 3
Thrush 2
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Steroids and particularly ACTH may be useful in 
treatment of children with intractable seizure but most 
of them indicate that effects of steroids were transient 
in half of the patients with initial significant response. 
The long-term efficacy was reported of ACTH therapy 
in controlling seizure in two patients. Long-term 
weekly ACTH therapy for duration of one year was 
effective and seizure was completely controlled (12).
In our study, recurrence rate of seizure was less than 
50%. This difference may be ascribed to several factors 
such as drug dose, interval of ACTH injection, duration 
of treatment, type of seizure, number of patients, 
different etiology. 
Several factors may be important in effectiveness of 
ACTH in intractable seizures. Underlying disease, 
abnormalities of brain imaging, seizure types, duration 
of treatment, dose and interval of ACTH injection 
probably are the most important determinants, which 
25Iran J Child Neurol. SUMMER  2017  Vol 11 No 3
may play a role in effectiveness of treatment.
In our study, excellent response was observed in 
patients with history of infantile spasm. More than 80% 
reduction in seizure frequency in two and 50%-80% 
reduction in seizure frequency in one of these three 
patients with history of infantile spasm was observed 
3 months after cessation of treatment with ACTH. 
Although the number is too little for a definitive 
conclusion but this finding may suggest better response 
to ACTH in patients with history of infantile spasm.
Most of our cases had polymorph seizure (21 out of 
25). Video monitoring has not been performed for most 
of our cases, therefore, we could not exactly determine 
all seizure types and effects of ACTH on different types 
of seizure but according to parental reports, myoclonic 
and absence seizures were more responsive to ACTH. 
In this study, there was no relationship between 
response to ACTH and baseline variables including 
age, brain MRI, underlying disease and developmental 
status but because of small sample size importance of 
this finding could not be overvalued.
We observed frequent side effects including irritability, 
edema and weight gain in most of our patients but in no 
cases, a serious problem was observed. In cases with 
probable side effects, complete clinical and laboratory 
evaluation was performed and after rule out of serious 
side effects, treatment was continued. Similar side 
effects have been reported in previous studies in which 
ACTH has been used (4, 8).
In our study, in no patient, seizure frequency increased, 
but recurrence of seizures, though with less frequency, 
was observed in three of the cases with moderate initial 
response before next dose of weekly ACTH injections. 
For treatment purpose in these cases, injection interval 
decreased to 5 d with good result.
Because of high frequency of mentioned side effects, 
which causes severe concern and anxiety in patient’s 
family and may finally end to premature cessation of 
treatment, we recommend that hospitalization of all 
patients for a period of 10-14 d at the onset of treatment 
and a close follow up of the patients be considered 
during treatment period. 
In our study, we have not performed video EEG 
monitoring in most of our patients so we could not 
exactly determine all seizure types in the patients. In 
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addition, we did not hospitalize the patients and follow 
the response to video monitoring. Because of this 
inevitable limitation, response to ACTH was judged 
according to parent’s recorded observations.
There is no clear data regarding appropriate dose, 
duration, and interval of drug administration. This 
drug may be more effective for treatment of pharmaco 
resistant seizures if proper dose, interval, and duration 
of treatment could be determined. Further large-scale 
studies focusing on these limitations are required to 
clarify these important issues.
in Conclusion, ACTH therapy is relatively safe and 
effective for patients with intractable seizures. Our 
result is consistent with the few studies reporting the 
effective ACTH treatment in children with intractable 
epilepsy other than spasm. 
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